Dynamic assessment of executive function disorders in patients with recurrent depressive disorder and bipolar affective disorder during psychopharmacotherapy

Dynamic assessment of executive function disorders in patients with recurrent depressive disorder and bipolar affective disorder during psychopharmacotherapy

 

Authors

 

N.S. Smirnova

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation

G.G. Simutkin

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation

A.K. Surovtseva

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation

S.N. Vasilieva

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation

E.V. Didenko

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation

 

https://doi.org/10.26617/1810-3111-2024-4(125)-97-103

 

Journal: Siberian Herald of Psychiatry and Addiction Psychiatry. 2024; 4 (125):  97-103.

 

Abstract

Introduction. Impairment of cognitive functioning, including executive functions in affective disorders, is a press-ing clinical problem. Objective: to conduct a comparative analysis of executive function disorders in patients with recurrent depressive disorder (RDD) and bipolar affective disorder (BD) with their clinical and dynamic assessment during psychopharmacotherapy. Materials. At the Affective States Department of Mental Health Research Institute of Tomsk National Research Medical Center, 32 patients (24 women, 8 men) with RDD aged 31 to 54 years and 14 patients (7 men and 7 women) with a current depressive episode within BD aged 20 to 41 years were examined. An-tidepressants with a procognitive effect were used as basic therapy for RDD and BD. Methods. Dynamic assessment of the presence and severity of various aspects of executive function disorders in groups of patients with RDD and bipolar disorder (before treatment and by day 28 of therapy) was performed using psychodiagnostic testing: the Tower of London Test (Shallis T., 1982), a test for verbal and semantic fluency, Schulte tables (Schulte W.) for studying the ability to concentrate as a leading component in the implementation of the executive function. Statistical processing of the results was performed using the STATISTICA version 10.0 package for Windows. Results. Executive dysfunction is specific for affective disorders with a relatively greater severity in bipolar disorder. Against the background of therapy, patients with RDD show a more pronounced dynamics of improvement in executive functions than patients with bipolar disorder, but the clinical significance of this effect requires additional study. Conclusion. Taking into account executive function impairments may be important for optimizing a personalized approach when prescribing complex psychopharmacotherapy in affective disorders.

 

Keywords: affective disorders, type of course, cognitive impairments, psychopharmacotherapy.

 

Article (pdf)

 

Contacts

This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Materials  

 

For citation: Smirnova N.S., Simutkin G.G., Surovtseva A.K., Vasilieva S.N., Didenko E.V. Dynamic assessment of executive function disorders in patients with recurrent depressive disorder and bipolar affective disorder during psychopharmacotherapy. Siberian Herald of Psychiatry and Addiction Psychiatry.2024; 4 (125): 97-103. https://doi.org/10.26617/1810-3111-2024-4(125)-97-103

 

REFERENCES

  1. MosolovSN, KostyukovaEG, KuzavkovaMV. Bipolar disorder: diagnostics and therapy / S.N. Mosolov, ed. Moscow: MEDpressinform Publishing House, 2008:384 (in Russian).
  2. Kurtz MM, Gerraty RT. A meta-analytic investigation of neurocognitive deficits in bipolar illness: profile and effects of clinical state. Neuropsychology. 2009 Sep;23(5):551-62. doi: 10.1037/a0016277. PMID: 19702409; PMCID: PMC2804472.
  3. Cho Y, Lee JK, Kim DH, Park JH, Choi M, Kim HJ, Nam MJ, Lee KU, Han K, Park YG. Factors associated with quality of life in patients with depression: A nationwide population-based study. PLoS One. 2019 Jul 11;14(7):e0219455. doi: 10.1371/journal.pone.0219455. PMID: 31295291; PMCID: PMC6623963.
  4. Marazziti D, Consoli G, Picchetti M, Carlini M, Faravelli L. Cognitive impairment in major depression. Eur J Pharmacol. 2010 Jan 10;626(1):83-6. doi: 10.1016/j.ejphar.2009.08.046. Epub 2009 Oct 14. PMID: 19835870.
  5. Keilp JG, Gorlyn M, Oquendo MA, Burke AK, Mann JJ. Attention deficit in depressed suicide attempters. Psychiatry Res. 2008 May 30;159(1-2):7-17. doi: 10.1016/j.psychres.2007.08.020. Epub 2008 Mar 10. PMID: 18329724; PMCID: PMC2518449.
  6. Reppermund S, Ising M, Lucae S, Zihl J. Cognitive impairment in unipolar depression is persistent and non-specific: further evidence for the final common pathway disorder hypothesis. Psychol Med. 2009 Apr;39(4):603-14. doi: 10.1017/S003329170800411X. Epub 2008 Jul 30. PMID: 18667101.
  7. Yanushko MG, Shamanina MV, Keefe RSE, Shipilin MJ. Cognitive impairment in affective disorders. Evaluation approaches and possibilities of correction. Current Therapy of Mental Disorders. 2015;(4):8-13 (in Russian).
  8. Perini G, Cotta Ramusino M, Sinforiani E, Bernini S, Petrachi R, Costa A. Cognitive impairment in depression: recent advances and novel treatments. Neuropsychiatr Dis Treat. 2019 May 10;15:1249-1258. doi: 10.2147/NDT.S199746. PMID: 31190831; PMCID: PMC6520478.
  9. Akhapkin RV, Fayzulloev AZ. Structure of cognitive impairments in patients with nonpsychotic depressive disorders. Kremlin Medicine. Clinical Bulletin. 2020;3:54-64 doi: 10.26269/333m-6094(in Russian).
  10. Turusheva A, Frolova E. The relationship between depression and cognitive impairment in the Russian population of people over 65 years old: results of the Crystal study. Doctor. 2018;29(9):26-30. https://doi.org/10.29296/25877305-2018-09-06 (in Russian).
  11. Kremen WS, Faraone SV, Seidman LJ, Pepple JR, Tsuang MT. Neuropsychological risk indicators for schizophrenia: a preliminary study of female relatives of schizophrenic and bipolar probands. Psychiatry Res. 1998 Jul 13;79(3):227-40. doi: 10.1016/s0165-1781(98)00042-0. PMID: 9704870.
  12. Keilp JG, Gorlyn M, Russell M, Oquendo MA, Burke AK, Harkavy-Friedman J, Mann JJ. Neuropsychological function and suicidal behavior: attention control, memory and executive dysfunction in suicide attempt. Psychol Med. 2013 Mar;43(3):539-51. doi: 10.1017/S0033291712001419. Epub 2012 Jul 10. PMID: 22781400; PMCID: PMC3767483.
  13. Maalouf FT, Brent D, Clark L, Tavitian L, McHugh RM, Sahakian BJ, Phillips ML. Neurocognitive impairment in adolescent major depressive disorder: state vs. trait illness markers. J Affect Disord. 2011 Oct;133(3):625-32. doi: 10.1016/j.jad.2011.04.041. Epub 2011 May 26. PMID: 21620477; PMCID: PMC4119611.
  14. Zuckerman H, Pan Z, Park C, Brietzke E, Musial N, Shariq AS, Iacobucci M, Yim SJ, Lui LMW, Rong C, McIntyre RS. Recognition and treatment of cognitive dysfunction in major depressive disorder. Front Psychiatry. 2018 Dec 4;9:655. doi: 10.3389/fpsyt.2018.00655. PMID: 30564155; PMCID: PMC6288549.
  15. Semkovska M, Quinlivan L, O'Grady T, Johnson R, Collins A, O'Connor J, Knittle H, Ahern E, Gload T. Cognitive function following a major depressive episode: a systematic review and meta-analysis. Lancet Psychiatry. 2019 Oct;6(10):851-861. doi: 10.1016/S2215-0366(19)30291-3. Epub 2019 Aug 15. PMID: 31422920.
  16. Diamond A. Executive functions. Annu Rev Psychol. 2013;64:135-68. doi: 10.1146/annurev-psych-113011-143750. Epub 2012 Sep 27. PMID: 23020641; PMCID: PMC4084861.
  17. Lam RW, Kennedy SH, Mclntyre RS, Khullar A. Cognitive dysfunction in major depressive disorder: effects on psychosocial functioning and implications for treatment. Can J Psychiatry. 2014 Dec;59(12):649-54. doi: 10.1177/070674371405901206. PMID: 25702365; PMCID: PMC4304584.
  18. Friedman NP, Miyake A. Unity and diversity of executive functions: Individual differences as a window on cognitive structure. Cortex. 2017 Jan;86:186-204. doi: 10.1016/j.cortex.2016.04.023. Epub 2016 May 10. PMID: 27251123; PMCID: PMC5104682.
  19. Godefroy O, Cabaret M, Petit-Chenal V, Pruvo JP, Rousseaux M. Control functions of the frontal lobes. Modularity of the central-supervisory system? Cortex. 1999 Feb;35(1):1-20. doi: 10.1016/s0010-9452(08)70782-2. PMID: 10213531.
  20. Galkin SA, Vasilieva SN, Simutkin GG, Ivanova SA. Executive dysfunction in affective disorders: differences in bipolar affective disorder and depressive episode. Bulletin of Siberian Medicine. 2022;21(3):28-33. https://doi.org/10.20538/1682-0363-2022-3-28-33 (in Russian).
  21. Galkin SA, Ivanova SA, Bokhan NA. Executive functions and their role in predicting therapeutic response in patients with depressive disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(5):40-44. https://doi.org/10.17116/jnevro202112105140 (in Russian).
  22. Shmukler AB. Role of cognitive disturbances in evaluation of pathogenesis, clinical picture and treatment of depression. Social and Clinical Psychiatry. 2016;26(4):57-62 (in Russian).
  23. Chakrabarty T, Hadjipavlou G, Lam RW. Cognitive Dysfunction in Major Depressive Disorder: Assessment, Impact, and Management. Focus (Am Psychiatr Publ). 2016 Apr;14(2):194-206. doi: 10.1176/appi.focus.20150043. Epub 2016 Apr 7. PMID: 31975803; PMCID: PMC6519654.
  24. Post RM, Fleming J, Kapczinski F. Neurobiological correlates of illness progression in the recurrent affective disorders. J Psychiatr Res. 2012 May; 46(5):561-73. doi: 10.1016/j.jpsychires.2012.02.004. Epub 2012 Mar 23. PMID: 22444599.
  25. Galkin SA, Ryazantseva UV, Simutkin GG, Ivanova SA, Bokhan NA. Possible neurophysiological markers for the differential diagnosis of bipolar and unipolar affective disorders. Siberian Herald of Psychiatry and Addiction Psychiatry. 2021;4(113):14-21. https://doi.org/10.26617/1810-3111-2021-4(113)-14-21 (in Russian).
  26. Culbertson WC, Zillmer EA. The Tower of London Drexel University (TOLDX). Manual. North Tonawanda. NY: Multi-Health Systems, 2001.
  27. Strauss E, Sherman EMS, Spreen O. A compendium of neuropsychological tests: administration, norms, and commentary. 3 ed. New York: Oxford University Press, 2006:1216.
  28. Bown BT, Brignon M, Larsen KG. Comparison of the effectiveness of antidepressants in their impact on cognitive impairment in patients with major depressive disorder. Social and Clinical Psychiatry. 2018;28(2):45-49 (in Russian).
  29. MahableshwarkarAR, ZajekaJ, JacobsonV, ChenY, KeefeRSE. Efficacy of vortioxetine on cognitive functioning in patients with major depressive disorder. Social and Clinical Psychiatry. 2015;25(4):54-59 (in Russian).